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ABSTRACT 
 
Background and Objectives: The emergence of plasmid-mediated AmpC (pAmpC) β-lactamases conferring resistance to 
third-generation cephalosporins has become a major clinical concern worldwide. The aims of this study were to determine 
the prevalence of pAmpC-producing E. cloacae isolates and typing of them in Qazvin and Tehran provinces, Iran.
Materials and Methods: A total of 120 cefoxitin non-susceptible isolates of E. cloacae were obtained from educational hos-
pitals of Qazvin and Tehran, Iran. Bacterial identification was performed by standard laboratory methods and API 20E strips. 
Susceptibility to cefoxitin was determined by Kirby-Bauer disk diffusion method. PCR and sequencing were employed to 
detect pAmpC families’ genes (ACC, FOX, MOX, DHA, CIT and EBC) and the clonal relatedness of pAmpC-positive iso-
lates was evaluated by enterobacterial repetitive intergenic consensus (ERIC)-PCR method.
Results: In total, 20 (16.7%) isolates of E. cloacae were positive for presence of pAmpC genes among those blaDHA-1 (14.2%) 
was the most common gene followed by blaCMY-2 (2.5%). Results of ERIC-PCR showed that that the prevalence of DHA-1 
and CMY-2-producing E. cloacae isolates was not due to clonal outbreaks.
Conclusion:  In present study, we showed the first emergence of DHA-1 and CMY-2 types of pAmpC-producing E. cloacae 
isolates in Iran. The appearance of pAmpC should be considered as a warning for the implementation of appropriate infection 
control and therapeutic policies in order to prevent the dissemination of these resistant organisms in our hospital settings.
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INTRODUCTION
Enterobacter cloacae is a prevalent opportunistic 
pathogen which is associated with nosocomial infec-
tion in hospital settings (1). The most common caus-
ing infections of this organism are the urinary tract, 
lower respiratory tract, skin and soft tissue, and cen-
tral nervous system infections (2). The β-lactams are 
one of the most prescribed choices against bacterial 
infections (3). β-lactamase production is the major 
β-lactam resistance mechanism in Gram-negative 
bacteria, such as Enterobacteriaceae and Pseudomo-
nas aeruginosa (4). In recent years, emerging of new-
er β-lactamase enzymes, including extended-spec-
trum β-lactamases (ESBLs) and AmpC β-lactamases 
complicates the process of therapy and limits treat-
ment options (4, 5). The extensive and inappropriate 
use of β-lactam antibiotics are associated with the 
appearance of these resistant determinants, especial-
ly when third-generation cephalosporins are used to 
treat serious infections (6).
AmpC β-lactamase production is one of the mech-
anisms of resistance to β-lactam antibiotics in Gram 
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negative bacteria conferring resistance to a wide va-
riety of β-lactam antibiotics including 7-α-methoxy-
cephalosporins (cefoxitin or cefotetan), oxyimino 
cephalosporins (cefotaxime, ceftazidime, and ceftri-
axone), and monobactams (aztreonam) (7, 8). Resis-
tance due to pAmpC enzymes is less common than ex-
tended spectrum β-lactamases (ESBLs) production, 
however they have rapidly become a leading  clini-
cal concern due to their self-transmissibility which 
permits their spread among different bacteria (9-11). 
   AmpC β-lactamases are not inhibited by clavulan-
ic acid, sulbactam and tazobactam which generally 
inhibit the ESBL production (12-14). Although pAm-
pC enzymes most often found in nosocomial isolates 
of Escherichia coli and Klebsiella pneumoniae, but 
there are few published reports regarding occurrence 
of these enzymes in other genera of Enterobacteria-
ceae (15).
ACC, FOX, MOX, DHA, CIT and EBC are most 
commonly reported pAmpC genotypes, among 
those CMY-2-like enzymes are the most prevalent in 
clinical enterobacteial isolates, although the DHA-
like β-lactamases have also spread extensively (11). 
These enzymes confer a resistance pattern similar 
to the overproduction of chromosomal AmpC β-lac-
tamases, which may involve all β-lactam antibiotics 
except for carbapenems and cefepime (16).
Detection of pAmpC β-lactamase remains a chal-
lenge in clinical microbiology laboratories because 
there are no guidelines of Clinical and Laboratory 
Standards Institute (CLSI) for phenotypic detection 
of AmpC-producing organisms. Although several 
phenotypic tests are now available for detection of 
pAmpC among clinical isolates of Enterobacteriace-
ae but none of these tests are standardized and they 
are unreliable and unsuitable, resulting in misreport-
ing and treatment failures (8, 10). In addition, pheno-
typic tests do not differentiate between chromosomal 
and pAmpC genes (17). However, molecular charac-
terization is considered as the gold standard method 
(8). There was no report on prevalence of pAmpC 
β-lactamases in Enterobacter spp. in Iran. In this 
study, we describe the prevalence of pAmpC -encod-
ing genes in clinically E. cloacae isolates collected 
from two distinct provinces of Iran.
   
MATERIALS AND METHODS
 
  Study design and Bacterial isolates. During a 
16-month period from August 2012 to December 
2013, a total of 120 non-duplicate cefoxitin-resistant 
clinical isolates of E. cloacae were collected from 
different clinical samples of patients admitted to sev-
eral teaching hospitals of Qazvin, and Tehran. The 
isolates were collected from various clinical speci-
mens including urine, wound, sputum, bronchoalve-
olar lavage (BAL), trachea, blood, and cerebrospinal 
fluid. Isolates were obtained from patients admitted 
to intensive care units, internal medicine, infectious 
diseases, neurology, surgery, and orthopedic wards. 
Forty-eight patients (40%) were females and seventy 
two (60%) were males aged between 18 and 85 years 
with a mean of 49.3±17.4 years. Written informed 
consent was obtained from all subjects enrolled in 
this study. Isolates were identified using convention-
al laboratory techniques and confirmed by the API 
20 E (bioMérieux, France). They were stored at -70 
°C in trypticase soy broth containing 20% glycerol 
and sub-cultured twice prior to testing. 
In order to initial screen of pAmpC production, 
the antimicrobial susceptibility of isolates was de-
termined using Kirby-Bauer disc diffusion method 
against cefoxitin (30μg) as instructed by CLSI (18). 
Additionally, susceptibility to imipenem (10μg), and 
meropenem (10μg) was determined. Antibiotic discs 
were purchased from Mast (Mast Diagnostics Group 
Ltd, Merseyside, UK). E. coli ATCC 25922 and 
Pseudomonas aeruginosa ATCC 27853 were used as 
the quality control strains in antimicrobial suscepti-
bility testing.
Multiplex PCR and sequencing of pAmpC-en-
coding genes. Plasmid DNA from cefoxitin resistant 
E. cloacae isolates was extracted using extraction kit 
(Bioneer, Seoul, Korea). All cefoxitin-non suscep-
tible isolates (n=120), as putative AmpC producers, 
were tested by multiplex PCR assay to identify six 
family-specific AmpC genes including MOX, FOX, 
EBC, ACC, DHA and CIT as previously described by 
Pérez-Pérez et al. (Table 1) (15). Amplification reac-
tions were prepared in a total volume of 50 µl. Each 
reaction contained 20 mMTris-HCl (pH 8.4); 50 mM 
KCl; 0.2 mM each deoxynucleoside triphosphate; 1.5 
mM MgCl2; 0.6 µM primers and 1.25 U of Taq DNA 
polymerase. Template DNA (2 µl) was added to 48 µl 
of the master. PCR amplification was performed in a 
thermocycler (Applied Biosystems, USA) as follows: 
94 ̊C for 3 min and 35 cycles of 1 min at 94 ̊C, 1 min 
at specific annealing temperature for each primer 
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and 1 min at 64 ̊C. A final extension step of 10 min 
at 72 ̊C was performed. PCR products were electro-
phoresed on a 1% agarose gel at 100 V and then were 
stained with the ethidium bromide solution and final-
ly visualized in a gel documentation system (UVtec). 
The purified PCR products were sequenced by the 
Macrogen Company (South Korea) and sequence 
alignment and analysis were performed online using 
Table 1. Primers used for amplification of pAmpC genes in this study
            Genes
MOX-1,MOX-2,CMY-
1,CMY-8toCMY-11
LAT-1 to LAT-4, CMY-2 
to CMY-7, BIL-1
DHA-1, DHA-2
ACC
MIR-1T ACT-1
FOX-1 to FOX-5b
ERIC-PCR
                                Sequence (5´to 3')
F-GCTGCTCAAGGAGCACAGGAT
R-CACATTGACATAGGTGTGGTGC
F-TGGCCAGAACTGACAGGCAAA
R-TTTCTCCTGAACGTGGCTGGC
F-AACTTTCACAGGTGTGCTGGGT
R-CCGTACGCATACTGGCTTTGC
F-AACAGCCTCAGCAGCCGGTTA
R-TTCGCCGCAATCATCCCTAGC
F-TCGGTAAAGCCGATGTTGCGG
R-CTTCCACTGCGGCTGCCAGTT
F-AACATGGGGTATCAGGGAGATG
R-CAAAGCGCGTAACCGGATTGG
F-ATGTAAGCTCCTGGGGATTCAC
R-AAGTAAGTGACTGGGGTGAGCG
References
15
15
15
15
15
15
19
Table 2. Case histories and characteristics of the 20 pAmpC-producing E. cloacae isolates collected from Qazvin and Tehran 
hospitals
Isolates
En.c 2
En.c 5
En.c 18
En.c 20
En.c 22
En.c 34
En.c 36
En.c 37
En.c 39
En.c 40
En.c 43
En.c 55
En.c 56
En.c 73
En.c 74
En.c 92
En.c 97
En.c 101
En.c 112
En.c 120
City
Qazvin
Qazvin
Qazvin
Tehran
Tehran
Tehran
Tehran
Tehran
Tehran
Tehran
Tehran
Tehran
Qazvin
Tehran
Tehran
Tehran
Tehran
Tehran
Qazvin
Qazvin
Age (yr)/
gender
46/female
58/male
29/male
35/female
39/female
48/male
38/female
65/male
50/male
23/male
45/male
48/female
28/male
71/female
63/male
23/male
59/male
32/male
38/female
59/female
Ward
ICU
ICU
ICU
ICU
ICU
Internal
Internal
ICU
ICU
ICU
ICU
ICU
ICU
ICU
Infectious
Internal
Internal
Internal
ICU
Surgery
Source
Tracheal
Urine
Urine
Wound
Wound
Wound
Wound
Urine
Urine
Sputum
Wound
Wound
Urine
Blood
Tracheal
Urine
Wound
Wound
Urine
BAL
Susceptibility to
IMI               MEM
  S S
  R R
  R S
  S S
  S S
  S S
  S S
  S S
  S S
  S S
  S S
  S S
  S S
  S S
  S R
  S S
  S S
  S S
  S S
  R R
pAmpC gene
CMY-2       DHA-1 
   - +
   - +
   - +
   - +
   + -
   - +
   - +
   - +
   - +
   - +
   - +
   - +
   + -
   - +
   - +
   + -
   - +
   - +
   - +
   - +
BAL: bronchoalveolar lavage; ICU: Intensive Care Unit; IMI; imipenem, MEM; mero-
penem; S: Susceptible; R: Resistance
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the BLAST program of the National Center for Bio-
technology Information (www.ncbi.nlm.nih.gov).
ERIC-PCR analysis. The epidemiological rela-
tionships of pAmpC-producing E. cloacae isolates 
were analyzed by ERIC-PCR as previously de-
scribed. Cycling conditions were as follows: dena-
turation at 94 ̊C for 1 sec, annealing at 52 ̊C for 10 
sec, and extension at 72 ̊C for 35 sec for 30 cycles, 
followed by a final extension at 72 ̊C for 4 min. The 
resulting products were analyzed on 1.5% agarose 
gels. Fingerprints were compared visually, and the 
patterns differing by two or more bands were classi-
fied as different (19).
Statistical analysis. Statistical analysis was per-
formed for descriptive statistics, including frequen-
cies, cross tabulation of microbiological, clinical, and 
demographic characteristics using the computer soft-
ware program SPSS version 16.
 
RESULTS
During the study period, 120 cefoxitin non-suscep-
tible clinical isolates E. cloacae were recovered from 
different clinical specimens including urine (44 iso-
lates; 36.7%), wound (29 isolates; 24.2%), blood (18 
isolates; 15%), trachea (16 isolates; 13.3%), sputum 
(6 isolates; 5%), bronchoalveolar lavage (5 isolates; 
4.2%), and cerebrospinal fluid (2 isolates; 1.7%). Iso-
lates were obtained from patients admitted to the in-
tensive care units (52-43.3%), internal medicine (29-
24.2%), infectious diseases (14-11.7%), neurology 
(6-5%), surgery (10-8.3%), and orthopaedic (9-7.5%) 
wards. In total, 19 (15.8%) and 14 (11.7%) isolates 
were non-susceptible to imipenem and meropenem, 
respectively.
PCR and sequencing showed that 20 (16.7%) iso-
lates were positive for pAmpC among them blaDHA-1 
(14.2%) was the most common gene followed by 
blaCMY-2 (2.5%). The isolates were negative for blaACC, 
blaFOX, blaMOX or blaEBC families. As shown in Table 
2, pAmpC-positive isolates were mostly recovered 
from wound (8-6.7%), followed by urine (7-5.8%) 
samples. The patients affected by these organisms 
were mostly admitted to ICU (13-10.8%) and the in-
ternal medicine (5-4.2%) wards.
ERIC-PCR. Seventeen isolates of DHA-1-produc-
ing E. cloacae showed ten different genotypic pat-
terns (data not shown), showing that both horizontal 
gene transfer and clonal expansion contribute to the 
spread of antibiotic resistance while 3 CMY-2-pro-
ducing isolates indicated different patterns.
DISCUSSION
   Emergence of pAmpC enzymes among Gram-neg-
ative bacteria especially E. cloacae is an important 
clinical concern which contributes to high rates of 
morbidity and mortality in hospital settings, in partic-
ular among ICU patients (11). AmpC β-lactamases are 
either plasmid or chromosomal mediated. In the late 
1980s, plasmid-borne AmpC cephalosporinases were 
detected on plasmids which facilitate their spread be-
tween the Enterobacteriaceae (10, 20). Detection of 
pAmpC-producing organisms is important to ensure 
effective therapeutic intervention and optimal clini-
cal outcomes (8). In Iran, AmpC detection is not rou-
tinely done in most laboratories. Up to date, there are 
rare reports to related incidence of plasmid-mediated 
AmpC in Enterobacter spp. worldwide. To the best of 
our knowledge, this is the first report of emergence of 
pAmpC in clinical isolates of E. cloacae in Iran.
   Based on our findings, the plasmid encoded AmpC 
genes were found in 20 (16.7%) isolates by PCR. 
The prevalence rate found in our study is lower than 
those reported by Wang and et al. from China (21), 
and Yusuf et al. form Nigeria (22) in which 35.06% 
and 18.8% of E. cloacae isolates were found to be 
AmpC producer, respectively. Plasmid AmpC β-lac-
tamases have been increasingly reported among oth-
er members of Enterobacteriaceae. Yamasaki et al. 
reported that 0.12% of E. coli, 0.13% of K. pneumo-
niae, 0.17% of K. oxytoca and 0.08% of P. mirabilis 
isolates in Japan were positive for pAmpC production 
(23). Li et al. from China reported that 4.29% K. pneu-
moniae, 1.91% of E. coli, and 3.03% of K. oxytoca 
were found to be positive for pAmpC (24).
  In Turkey, Yilmaz et al. using PCR reported that 
10.9% of E. coli and 3.6% of K. pneumoniae isolates 
were AmpC producers (25). In Egypt, Nevine Fam et 
al. reported that 28.3% of E.coli, Klebsiella spp. and P. 
mirabilis isolates were positive for AmpC production 
(10). In the another study from Egypt, 16.8% of ce-
foxitin resistant E. coli, K. pneumoniae, and P. mira-
bilis isolates were positive for the presence of pAmpC 
genes (17). Tan et al. reported that pAmpC was pres-
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ent in 26% of E. coli, Klebsiella spp., and P. mirabilis 
isolates in Singapore (26). These findings indicate that 
the rate of plasmid mediated AmpC β-lactmases is 
increasing among Enterobacteriaceae worldwide. We 
previously reported that 53 (44.2%) of E. cloacae iso-
lates were found to be extended-spectrum β-lactamase 
(ESBL) producers (6). It seems that, inappropriate 
and extensive use of broad spectrum antibiotics can 
contribute to the emergence of these resistant isolates 
in our hospital settings. Our study indicated that most 
pAmpC-producing E. cloacae isolates were frequent-
ly collected from the patients admitted to intensive 
care units. The ICU stay, exposure to third-generation 
cephalosporins, and use of invasive procedures such 
as urinary catheterization appear to predispose these 
patients to infections with these resistant organisms.
    In the current study, 83.3% of cefoxitin non-suscep-
tible E. cloacae isolates were negative for the pres-
ence of pAmpC, suggesting that other mechanisms 
might alternatively be contributed to the resistance, 
most importantly, the overexpression of chromosomal 
ampC, known to confer resistance to oxyimino-ceph-
alosporins in this organism, as well as impermeability 
or reduced expression of outer membrane proteins, 
and alteration in the expression of efflux pumps (27, 
28). 
   In the current study, 17 (14.2%) isolates of E. clo-
acae carried blaDHA-1 and 3 (2.5%) isolates carried 
blaCMY-2 gene. No blaACC, blaFOX, blaMOX or blaEBC fam-
ilies’ genes were detected. To the best of our knowl-
edge, this is first report of blaCMY-2 and blaDHA-1 genes 
in clinical isolates of E. cloacae in Iran. In a report 
from Iran, Tajbakhsh et al. reported the emergence of 
blaCMY-2 in Shigella sonnei phase II isolates (29). In 
Europe, Mata et al from Spain reported that CMY-
2 type was predominantly found in E. coli (70.7%) 
and Proteus mirabilis (95%) isolates whereas DHA-
1 type was more frequent in K. pneumoniae (62.5%) 
followed by CMY-2 type (30). In Africa, Nevine Fam 
and et al. from Egypt reported that CMY-2 was the 
most prevalent gene (70.5%) followed by DHA-1 
(23.5%) and CMY-4 (5.8%) in Enterobacterial clini-
cal isolates (10). In Asian countries, Song and et al. 
from Korea reported that DHA-1 (66.6%) was the 
most common type of AmpC β-lactamase followed by 
CMY-2 (20%), CMY-10 (6.6%) and CMY-11 (6.6%) 
(31). Yamasaki and et al. from Japan reported that 
69.0%, 20.7%, 6.9%, and 3.4% of pAmpC-produc-
ing enterobacterial species carried CMY-2, DHA-1, 
CMY-8, and MOX-1 genes, respectively (23). Li et 
al. from China reported that 96.7% and 3.3% pAm-
pC-producing K. pneumoniae isolates carried blaDHA-1 
and blaCMY-2 genes whereas 52.18% and 47.8% of E. 
coli isolates were positive for the presence of blaCMY-2 
and blaDHA-1 genes, respectively (24). Tan et al. from 
Singapore reported that CMY-like enzymes detected 
predominantly in E coli and DHA-like enzymes were 
frequently found in K. pneumoniae (26). 
   Since the pAmpC-producing isolates typically ex-
hibit resistance to several classes of β-lactam antibiot-
ics so carbapenem are used as a therapeutic of choice 
for treating  of serious infections caused by these or-
ganisms (4). However, we encountered a considerable 
rate of carbapenem resistance among E. cloacae iso-
lates in this study; 19 (15.8%) and 14 (11.7%) isolates 
were non-susceptible to imipenem and meropenem, 
respectively which would have more clinical impact 
if these strains become more prevalent in the future.
   In this study, ERIC-PCR analysis showed all blaC-
MY-2-positive isolates displayed different genotypic 
patterns and blaDHA-1-positive isolates presented ten 
different types; suggesting that the dissemination 
of these isolates was not due to a clonal outbreak. It 
could be explained by the fact that the isolates in the 
present study were collected from seven hospitals in 
Tehran, and five hospitals in Qazvin; two different lo-
cations in Iran.  
   In conclusion, the results of this study showed the 
emergence of blaDHA-1 and blaCMY-2 genes among the 
clinical isolates of E. cloacae in Iran. The emergence 
and spreading of these resistant determinates in our 
clinical settings emphasizes on the necessity for es-
tablishing tactful policies for infection control and an-
tibiotic therapy.
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